The Impact of Airway Allergic Diseases on Children's and Parents' Quality of Life

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age5-16
SponsorWenjing Zhou

About this trial

This prospective observational study aims to assess the health-related quality of life (HRQoL) of 200 children (ages 5-16) with bronchial asthma, allergic rhinitis, or both, and their 200 parents, comparing 100 children receiving specific immunotherapy with 100 receiving routine treatment. Using EQ-5D-Y(EuroQol five dimensions questionnaire, youth version), disease-specific scales, and newly developed Chinese versions of EQ-5D-Y and EQ-HWB-S (EuroQol health and well-being questionnaire, short version), the study evaluates HRQoL changes over 1 and 2 years and explores the impact on caregiver burden and spillover effects. A control group of 100 healthy children and their parents will be included. Data collection involves baseline and follow-up surveys, clinical data from medical records, and statistical analyses to compare treatment effects and validate measurement tools.

Eligibility criteria

Qualifiers

Aged 5-16 years;

Diagnosed with bronchial asthma, allergic rhinitis, or both (persistent, duration ≥4 weeks) by a respiratory or allergy specialist;

Guardian has signed the informed consent form;

Able to understand and complete the questionnaire;

Disqualifiers

Poor compliance;

Already received specific immunotherapy at another hospital;

Unable to independently read and complete the questionnaire;

Lost to follow-up or discontinued treatment.

Trial design

Treatments tested in this trial

  • Subcutaneous immunotherapy / Standard Treatment for Asthma and Rhinitis

Treatment groups

600 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Wenjing Zhou

Lead sponsor

RenJi Hospital

Sponsor institution